Coagulation factor VIII physiological binding partners (FVIII binding partners)

Coagulation factor VIII (FVIII) physiological binding partners represent a network of proteins and molecules that govern the stability, transport, and enzymatic activity of FVIII within the hemostatic system. The most critical partner is von Willebrand factor (vWF), which acts as a chaperone in the bloodstream, preventing FVIII degradation and premature clearance by masking specific domains. Upon vascular injury, FVIII is activated to FVIIIa and forms the intrinsic tenase complex with its partners Factor IXa and Factor X on activated phospholipid membranes, a step vital for the amplification of the coagulation cascade and thrombin generation. Other partners, such as low-density lipoprotein receptor-related protein 1 (LRP1) and the neonatal Fc receptor (FcRn), play key roles in the endocytosis and recycling of FVIII, respectively, thereby determining its circulatory half-life. Drugs targeting these interactions include bispecific antibodies like emicizumab, which mimics FVIII's cofactor function by bridging FIXa and FX, and engineered fusion proteins designed to optimize FVIII's pharmacokinetics by modulating its association with these physiological partners.

Other names

Factor VIII interactorsFVIII binding proteinsFVIII-associated proteinsFVIII physiological partners

Cofactor mimicry, replacement therapy, half-life extension via partner modification, and enzyme activation.